These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 29661477)

  • 21. Reverse J-Curve Relationship Between On-Treatment Blood Pressure and Mortality in Patients With Heart Failure.
    Lee SE; Lee HY; Cho HJ; Choe WS; Kim H; Choi JO; Jeon ES; Kim MS; Hwang KK; Chae SC; Baek SH; Kang SM; Choi DJ; Yoo BS; Kim KH; Cho MC; Kim JJ; Oh BH
    JACC Heart Fail; 2017 Nov; 5(11):810-819. PubMed ID: 29096790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial.
    Lewis EF; Claggett B; Shah AM; Liu J; Shah SJ; Anand I; O'Meara E; Sweitzer NK; Rouleau JL; Fang JC; Desai AS; Retta TM; Solomon SD; Heitner JF; Stamos TD; Boineau R; Pitt B; Pfeffer MA
    Circ Heart Fail; 2018 Mar; 11(3):e004457. PubMed ID: 29664406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential impact of heart rate and blood pressure on outcome in patients with heart failure with reduced versus preserved left ventricular ejection fraction.
    Maeder MT; Kaye DM
    Int J Cardiol; 2012 Mar; 155(2):249-56. PubMed ID: 21035207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical information from repeated blood pressure measurements in the management of heart failure with preserved ejection fraction.
    Wei FF; Zhou Y; Wu Y; Chen X; He J; Dong Y; Staessen JA; Liu C
    Hypertens Res; 2023 Feb; 46(2):475-484. PubMed ID: 36380201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT.
    Patel RB; Shah SJ; Fonarow GC; Butler J; Vaduganathan M
    Curr Heart Fail Rep; 2017 Aug; 14(4):217-222. PubMed ID: 28647918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heart Failure with Preserved Ejection Fraction Trials Have Heterogeneous Control Groups: a Comparison of Kaplan-Meier Curves.
    Luo H; Zhang C; Wang J; Zhu J; Jia X
    Cardiovasc Drugs Ther; 2018 Dec; 32(6):577-580. PubMed ID: 30187346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial.
    Pandey A; Berry JD; Drazner MH; Fang JC; Tang WHW; Grodin JL
    J Am Heart Assoc; 2018 Nov; 7(21):e009664. PubMed ID: 30376747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.
    Senni M; Gavazzi A; Oliva F; Mortara A; Urso R; Pozzoli M; Metra M; Lucci D; Gonzini L; Cirrincione V; Montagna L; Di Lenarda A; Maggioni AP; Tavazzi L;
    Int J Cardiol; 2014 May; 173(2):163-9. PubMed ID: 24630337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
    Carson PE; Anand IS; Win S; Rector T; Haass M; Lopez-Sendon J; Miller A; Teerlink JR; White M; McKelvie RS; Komajda M; Zile MR; McMurray JJ; Massie B
    JACC Heart Fail; 2015 Jun; 3(6):429-441. PubMed ID: 25982110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of diabetic retinopathy on prognosis of patients with heart failure with preserved ejection fraction.
    Yang Y; Zhou Y; Cao Y; Dong Y; Liu C; Zhu W
    Nutr Metab Cardiovasc Dis; 2022 Jul; 32(7):1711-1718. PubMed ID: 35606228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT.
    Grodin JL; Philips S; Mullens W; Nijst P; Martens P; Fang JC; Drazner MH; Tang WHW; Pandey A
    Eur J Heart Fail; 2019 May; 21(5):634-642. PubMed ID: 30714658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program.
    Meredith PA; Ostergren J; Anand I; Puu M; Solomon SD; Michelson EL; Olofsson B; Granger CB; Yusuf S; Swedberg K; Pfeffer MA; McMurray JJ
    J Am Coll Cardiol; 2008 Dec; 52(24):2000-7. PubMed ID: 19055992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction.
    Tsujimoto T; Kajio H
    Sci Rep; 2018 Jun; 8(1):9556. PubMed ID: 29934526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy.
    Krum H; Elsik M; Schneider HG; Ptaszynska A; Black M; Carson PE; Komajda M; Massie BM; McKelvie RS; McMurray JJ; Zile MR; Anand IS
    Circ Heart Fail; 2011 Sep; 4(5):561-8. PubMed ID: 21750125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
    Shah AM; Claggett B; Sweitzer NK; Shah SJ; Deswal A; Anand IS; Fleg JL; Pitt B; Pfeffer MA; Solomon SD
    Circ Heart Fail; 2015 Nov; 8(6):1052-8. PubMed ID: 26475142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leukocyte count and the risk of adverse outcomes in patients with HFpEF.
    Zhu Z; Zhou S
    BMC Cardiovasc Disord; 2021 Jul; 21(1):333. PubMed ID: 34233611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction.
    Joseph J; Claggett BC; Anand IS; Fleg JL; Huynh T; Desai AS; Solomon SD; O'Meara E; Mckinlay S; Pitt B; Pfeffer MA; Lewis EF
    JACC Heart Fail; 2016 Jun; 4(6):477-86. PubMed ID: 27039126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time in Target Range for Systolic Blood Pressure and Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.
    Huang R; Lin Y; Liu M; Xiong Z; Zhang S; Zhong X; Ye X; Huang Y; Zhuang X; Liao X
    J Am Heart Assoc; 2022 Apr; 11(7):e022765. PubMed ID: 35289182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
    Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
    Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.